Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin Pamoate IM vs SC in Advanced Prostate Cancer
NCT01257425Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of triptorelin pamoate in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 at 85 days. Started Dec 2010; status: completed.
02
Drugs
triptorelin pamoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01257425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257425.